Micronase Articles
M. cymbalaria improves glucose tolerance
16 March 2009
Onglyza boosts glucose control versus solo glyburide
15 September 2008
Glycemic control data added to Avandia label
21 July 2008
GSK shares slide 5.1% after Avandia linked to CV death risk; firm likely to cut guidance
28 May 2007
Australian PBS adds 45 drugs, widens use for 28
8 August 2005
FDA clears Alpharma's Glucovance copy
11 July 2005
Australian PBS new Rx listings aimed at seniors
11 April 2005
IVAX announces record sales in 2004
28 March 2005
Pharmaceutical Resources to buy Kali
19 April 2004
IVAX first to file for generic Glucovance
1 March 2004
Metformin GR meets goal in Ph III trial
22 December 2003
UPDATE: B-MS beats forecasts in 2nd qtr
4 August 2003
Merck KGaA seeks stand-alone marketing in Japan
17 March 2003
Merck KGaA sales are hit by generics
29 July 2002
Merck KGaA confident of surviving Glucophage declines
25 February 2002
Glucophage generics arrive on US market
4 February 2002
Update: Glucophage generic gets initial OK in USA
26 November 2001
Glucophage still driving Merck KGaA sales up to record heights
26 October 2001
Glucophage still driving Merck KGaA
27 July 2001
Merck KGaA sets out plan to become number one in core businesses
20 February 2001
Modernizing Merck KGaA looking to long-term growth from pharma
8 November 2000
B-MS gets OK for Glucophage XR
18 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
B-MS gains FDA OK for Glucovance
4 August 2000
Andrx and Novartis team up for metformin
13 March 2000
Hoechst/Rhone-Poulenc Merger Looks More Likely
17 November 1998
US Seniors "Pay Up To 1,407% More For Rx Drugs"
29 September 1998
Bad Times Soon Over, Says Hoechst Marion Roussel
12 March 1998
SkyePharma In Cash Crisis As Losses Double
18 September 1997
US Economic Slowdown Affects Larger Firms
7 August 1995
Black & Edgington Enters Generic Market
3 April 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
End Of Year Encouraging For US Companies
6 February 1995
E Merck Buys R-P'sStake In Lipha
16 January 1995
Glucophage Approval
9 January 1995
US FDA Concern over "Therapeutic Class Wars"
28 November 1994
Upjohn "Violated State Business Practice Laws"
8 August 1994
LILLY TO MARKET GENERIC TAGAMET
25 April 1994
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
UPJOHN APPROVAL
13 December 1993
UPJOHN PACT WITH GENEVA EXTENDED
5 April 1993
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
WORLD ENDOCRINE MARKET AND FORECASTS
29 March 1993
RISK YEARS AHEAD FOR UPJOHNFOR UPJOHN
22 March 1993
GENERIC HALCION AND XANAX IN USA
1 February 1993
Hoechst Roussel has no plans to market Glubate
22 June 1992
UPJOHN'S GLYNASE APPROVED IN USA
27 April 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
UPJOHN UPDATES ON R&D PROGRESS
13 April 1992
RECORD 4TH QTR FROM US DRUG COMPANIES
10 February 1992
Showing 1-57 of 57 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
